Prognostic Significance of Supraclavicular Lymph Nodes and Pleural Effusion In Small Cell Lung Cancer.
10.4046/trd.2001.50.1.84
- Author:
Mi Jeong KIM
;
Seung Beom HAN
;
Jin Ho KWAK
;
Doo Young KWON
;
Min Su KIM
;
Won Il CHOI
;
Young June JEON
;
Jae Yong PARK
;
Tae Hoon JUNG
- Publication Type:Original Article
- Keywords:
Small cell lung cancer(SCLC);
Survival;
Supraclavicular lymph node(SCLN);
Pleural effusion
- MeSH:
Gyeongsangbuk-do;
Humans;
Lymph Nodes*;
Neoplasm Metastasis;
Pleural Effusion*;
Radiotherapy;
Retrospective Studies;
Small Cell Lung Carcinoma*;
Survival Rate;
United States Department of Veterans Affairs
- From:Tuberculosis and Respiratory Diseases
2001;50(1):84-93
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUNDS: In the absence of distant metastasis, small cell lung cancer (SCLC) patients presenting with supraclavicular lymph node (SCLN) involvement and pleural effusion can benefit from thoracic radiotherapy. But there are some debate as to the prognostic significance of both SCLN involvement and pleural effusion. The purpose of this study was to determine the prognostic significance of SCLN involvement and pleural effusion in SCLC. METHODS: Two Hundred and fifteen patients with histologically confirmed small cell lung cancer, who were treated either at the Keimyung university Dongsan hospital and Kyungpook national university hospital from January 1994 to June 1998, were evaluated retrospectively. The patients were classified as having either limited or extensive stage using the Veterans Administration staging system. RESULTS: SCLN was presented in 10.5% of patients(n=21). The median survival was 247 days for patients with SCLN(n=21) and 264 days for patients without(n=194) (p=0.52). After treatment, the median survival was 298 days for patients with SCLN(n=13) and 348 days for patients without(n=115) (p=0.52). SCLN involvement was not correlated with the presence of distant metastases. Medican survival was 459 days for patients with a limited stage without SCLN(n=66), 650 days for those with a limited stage with SCLN (n=7) (p=0.96). Pleural effusion was presented in 24.7% of patients(n=52). The median survival was 198 days for patients with pleural effusion(n=52) and 275 days for patients without(n=163) (p<0.05). After treatment, the median survival was 294 days for patients with a pleural effusion(n=25) and 286 days for patients without(n=103) (p=0.39). The presence of pleural effusion was not correlated with that of distant metastases. The median survival was 395 days for patients with a limited stage without a pleural effusion(n=63), 451 days for those with a limited stage with pleural effusion(n=10) (p=0.92). CONCLUSIONS: In this study, SCLN involvement does not explain the poor survival rate and the relevance to extensive staged disease. Furthermore, the existence of a pleural effusion did not correlated with the presence of distant metastases. However, the presence of a pleural effusion appears to be a minor prognostic factor in our study. Therefore supraclavicular lymph node justify any amendment to the staging system currently used.
